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No Downstaging After Short -Term Preoperat i ve
Radiotherapy in Recta l Cancer Pat ients
By C.A.M. Marijnen, I.D. Nagtegaal, E. Klein Kranenbarg, J. Hermans, C.J.H. van de Velde, J.W.H. Leer,
and J.H.J.M. van Krieken for the Pathology Review Committee and the Cooperative Clinical Investigators
Purpose: In retrospective studies, total mesorectal
excision (TME) surgery has been demonstrated to result
in a reduction in the number of local recurrences of
rectal cancer. Reports on improved local control after
preoperative, hypofractionated radiotherapy have led
to the introduction of a randomized multicenter trial to
evaluate the effect of TME surgery with and without
preoperative radiotherapy. Treatment with preopera-
tive radiotherapy might have an effect on the patho-
logic characteristics that determine staging of rectal
cancer. We investigated the occurrence of downstaging
in rectal cancer patients treated with and without pre-
operative radiotherapy.
Patients and Methods: We analyzed the differences
in tumor size, number of examined lymph nodes, tu-
mor-node-metastasis stage, and histopathologic fea-
tures in 1,321 patients entered onto a randomized trial.
The trial compared preoperative radiotherapy (5 3 5
Gy) followed by TME surgery with TME surgery alone.
Patients who had an interval of more than 10 days
between the start of radiotherapy and surgery were
excluded from analysis.
Results: Differences were observed in tumor size
(P < .001) and total number of examined lymph nodes
(P < .001). No difference in tumor or node classifica-
tion was detected. The irradiated group demon-
strated more poorly differentiated tumors as well as
more mucinous tumors.
Conclusion: In rectal cancer patients, short-term,
preoperative radiotherapy with 5 3 5 Gy does not lead
to downstaging if the interval between the start of
radiotherapy and surgery does not exceed 10 days.
J Clin Oncol 19:1976-1984. © 2001 by American
Society of Clinical Oncology.
IN RECTAL CANCER, the most important predictivefactor for survival or recurrence after potentially cura-
tive surgery is the tumor-node-metastasis stage of the
disease. This is determined by the depth of penetration
through the bowel wall and the presence and number of
tumor-containing lymph nodes. Both of these criteria can
only be determined postoperatively.
In attempt to reduce the high local recurrence rates in
rectal cancer patients after curative surgery, the value of
additional preoperative1-10 or postoperative11-15 radiother-
apy (RT) has been investigated in a series of clinical trials.
Treatment with preoperative RT might have an effect on the
pathologic characteristics that determine staging in rectal
cancer patients. If such an effect occurs, the staging of rectal
cancer patients who undergo only potentially curative sur-
gery will be systematically different from the staging of
patients who receive preoperative RT followed by curative
surgery. As a consequence, migration of patients from one
stage to another might occur. This phenomenon, which
sometimes is called Will Rogers phenomenon, is well
documented in gastric cancer after D1 or D2 resection.16,17
The possible occurrence of downstaging is important to
decisions for which staging is relevant, for the selection of
patients for adjuvant therapy, and for comparison of differ-
ent treatment strategies.
In a large Swedish rectal cancer trial, preoperative hypo-
fractionated RT resulted in better local control than postop-
erative RT.1 Recent results of the SRC trial demonstrated
reduced local recurrence rates and improved overall sur-
vival with a short-term 5 3 5 Gy preoperative RT regimen
compared with surgery alone.10 This trial demonstrated an
imbalance in Dukes’ cancer stage groups, with more pa-
tients at Dukes’ A and Dukes’ B in the combined versus the
surgery arm, which was considered a result of downstaging
caused by the preoperative RT.
The beneficial effect of preoperative RT demonstrated in
the SRC trial was observed in combination with standard
surgery.10 The acknowledgment of the important role of
circumferential margin involvement in the local recurrence
of rectal cancer18 has led to the introduction of total
mesorectal excision (TME) surgery, as advocated by
Heald19 and Enker.20
To analyze whether preoperative RT is beneficial in
TME-treated patients, a randomized, international multi-
center trial was conducted under the auspices of the Dutch
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Colorectal Cancer Group to evaluate the effect of preoper-
ative, hypofractionated RT and TME surgery versus TME
surgery alone.21 The overall results are expected to be
published in 2001. We have analyzed currently the occur-
rence of stage migration as a result of preoperative RT in
patients entered onto this study.
The effect of RT on pathologic characteristics, and
consequently on the occurrence of downstaging in rectal
cancer, depends on total dose, fractionation size, and the
interval between the start of RT and the day of surgery,
which is called the overall treatment time (OTT). Trials on
which patients have an OTT greater than 4 weeks generally
demonstrate downstaging. Some trials have reported a
decrease in the number of patients with involved lymph
nodes after administration of 5 3 5 Gy.8,22 The present
study was undertaken to assess the effect of short-term
preoperative RT on tumor characteristics such as staging,
grading, nodal spread, and size in resected rectal cancer
specimens from a large multicenter trial with standardized
RT, surgery, and pathology.21
PATIENTS AND METHODS
Study Population
Primary rectal cancer patients who were included in a large multi-
center trial in the Netherlands were studied. From January 1996
through December 1999, more than 1,500 patients were randomized to
receive preoperative RT followed by standardized TME surgery or
TME surgery alone.
Patients entered onto the study were required to have biopsy
confirmation of rectal adenocarcinoma, resectable tumor as judged by
clinical examination, tumor within 15 cm of the anal verge, no signs of
distant metastases, and no hereditary polyposis. Patients in whom a
malignancy was diagnosed previously, or who had received either
chemotherapy or RT to the pelvis, were not included in the study.
Furthermore, patients had to be considered fit for surgery as well as for
RT. Informed consent was obtained from all patients.
Randomization to RT followed by TME surgery or TME surgery
alone occurred only after stratification for surgical institute and
expected type of resection. Central randomization was performed with
balanced lists and a block size of six. A total of 1,530 patients were
included on the trial, of which 117 turned out to be ineligible for
reasons listed in Table 1. To evaluate the effect of short-term preop-
erative RT on pathologic tumor characteristics, patients also were
excluded from analysis in the RT group because either the total dose
received was less than 25 Gy (n 5 14), or the time interval between the
start of radiation and surgery was greater than 10 days (n 5 78). Thus,
1,321 patients remained assessable.
Preoperative RT
The patients assigned to preoperative RT received a total dose of 25
Gy in five fractions for 5 to 7 days. The prescribed dose was specified
according to the guidelines in the International Commission on Radi-
ation Units Report 50.23 The clinical target volume included the
primary tumor and the mesentery, with vascular supply that contained
the perirectal, presacral, and internal iliac nodes (up to the S1-S2
junction). The upper border of the planning target volume was L5-S1
in 84% of patients and S1-S2 in 16% of patients. The perineum was
included if an abdominoperineal resection was planned, whereas the
lower border was 3 cm above the anal verge if the planned operation
was a low anterior resection. The irradiation was administered with a
four-portal field in 26% of patients and with a three-portal field in 74%
of patients.
Surgery
According to the protocol, surgery was to be performed within 10
days after the first day of irradiation. All patients underwent surgery
according to the TME principles.19 The main principles of this
operative technique involve sharp dissection within the true pelvis
around the integral mesentery under direct vision, envelopment of the
entire midrectum, and preservation of the hypogastric plexus.
Pathology Procedures
Standardized routine pathology examinations were performed in the
pathology laboratories of the referring hospitals as has been described
by Quirke et al.24 Pathologic information for all patients’ resected
tumors was recorded prospectively by pathologists from the referring
hospital on a standard pathology case record form. A pathology quality
manager and a pathology review committee were installed to ensure
consistent quality of all pathology data and procedures.25
Careful examination of the circumferential resection margin was
performed, and tumor invasion of the bowel wall and surrounding
tissue was investigated. The largest diameter of the tumor was
registered after fixation of the specimen. The specimens were examined
for lymph nodes, and all lymph nodes found were processed for
microscopic investigation.
Tumor staging was performed by use of the tumor-node-metastasis
classification,26 and the Jass classification27 was used by the pathology
review committee. A summary of the Jass classification is provided in
the Appendix. In addition, the pathology review committee classified
the tumors according to their histologic differentiation as well differ-
entiated, moderately differentiated, poorly differentiated, and undiffer-
entiated adenocarcinoma. The World Health Organization criteria as
Table 1. Patients Excluded From Analysis
RT 1 TME TME Total
Randomized 761 769 1530
Ineligible at randomization 22 27 49
No adenocarcinoma 4 3 7
Other/previous malignancy 10 15 25
Double tumor 1 5 6
Other 7 4 11
Ineligible after randomization 45 23 68
Withdrawn consent 11 2 13
Sigmoid carcinoma 2 — 2
Irresectable/M1 on CT scan 9 — 9
RT not possible 4 — 4
Other 5 1 6
No resection 14 20 34
Compliance RT , 100% 92 92
Dose , 25 Gy 14 — 14
OTT . 10 days 78 — 78
Total analyzed 602 719 1321
Abbreviation: CT, computed tomography.
1977PREOPERATIVE RADIOTHERAPY IN RECTAL CANCER
Downloaded from ascopubs.org by Radboud University Nijmegen on March 20, 2019 from 131.174.248.154
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
presented in 1976 by Morson and Sobin,28 with the modification of
Blenkinsopp et al,29 were used. The grading decision was based on the
least differentiated area. The tumor was considered mucinous if more
than 50% of the adenocarcinoma was mucinous.
Data Collection and Statistics
All case record forms were sent to the central data office at the
department of surgery in Leiden. After the data were checked, they
were entered in a database and analyzed with the SPSS 9.0 software for
Windows (SPSS, Inc, Chicago, IL).
Mann-Whitney U tests were used to compare quantitative and ordered
variables, and Student’s t test was used to analyze differences in normally
distributed data between the two groups. x2 tests were used to compare
proportions. A P value # 0.05 was considered statistically significant.
Previous Randomized Trials
To compare the effect of preoperative RT on stage migration, all
randomized trials with preoperative RT were analyzed. The difference
in the percentage of patients with tumor-node-metastasis stage III
disease in the nonirradiated group, minus the RT plus surgery group,
was calculated and plotted graphically with 95% confidence intervals.
RESULTS
Patient Characteristics
Table 2 lists distributions of age, sex, tumor localization,
operation type, and distant metastases for the two treatment
arms. There were no significant differences in these factors
among the individual treatment arms. For the patients
treated with RT, the time from initiation of RT up to and
including the day of surgery (the OTT) is listed in Table 2.
Pathologic Staging Characteristics
The mean tumor size (largest diameter) was significantly
smaller in the irradiated group than in the surgery-only
patient group (Table 3). The mean diameter of irradiated
tumors was 4.0 cm compared with 4.5 cm for the nonirradiated
tumors (P , .001). Nonetheless, there was no significant
difference in tumor classification between the groups.
The total number of lymph nodes examined was signifi-
cantly smaller in the irradiated group as compared with the
nonirradiated group (Table 3; P , .001). Overall, the mean
value of examined lymph nodes was 9.7 in the control group
and 7.7 in the irradiated group. There was no difference
between the groups in the mean number of positive lymph
nodes: 1.6 in the RT group and 1.9 in the control group. In
addition, in stage III tumors only, no difference between the
number of involved lymph nodes was observed. The distri-
bution between both groups with regard to node classifica-
tion was balanced: 39% nodal involvement in the combined
treatment arm and 42% involvement in the surgery-only
arm. The distribution of tumor-node-metastasis stages was
similar between both treatment arms (Fig 1). The number of
patients with tumor-node-metastasis stage III was 34% in
the irradiated group and 38% in the nonirradiated group.
Histopathologic Characteristics
The differentiation grades demonstrated more poorly
differentiated tumors in the irradiated group than in the
non irradiated group (Table 3; P , .001). There were also
Table 2. Clinical Characteristics of Patients in the Irradiated and
Nonirradiated Groups
Characteristics
RT 1 TME
(n 5 602) TME (n 5 719)
No. % No. %
Age, years
Mean 64.1 64.1
Range 26-88 23-92
Sex
Male 402 67 455 63
Female 200 33 264 37
Distance from anal verge
0-5 cm 174 29 224 32
5-10 cm 250 42 282 40
10-15 cm 169 29 202 28
Missing 9 11
Operation type
Abdominoperineal
resection
183 31 220 30
Low anterior resection 381 63 465 65
Hartmann 38 6 34 5
Distant metastases
No 568 94 679 94
Yes 34 6 40 6
OTT
6 2 0.3 —
7 16 3 —
8 237 40 —
9 218 36 —
10 129 21 —
Fig 1. Distribution of tumor-node-metastasis stage by randomization arm.
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significantly more mucinous tumors in the first group
(P , .001).
The proportion of peritumoral lymphocytic infiltration
was scored on slides stained with hematoxylin and eosin.
The irradiated tumors demonstrated extensive lymphoid
reaction in 6.8% of the cases versus 17.9% in the nonirra-
diated tumors (P , .001). The type of invasion (circum-
scribed v diffuse) did not vary between the groups. The
distribution over the Jass classification demonstrated a
lower Jass classification in the irradiated group (Fig 2).
Previous Randomized Trials
To compare the effect of different preoperative RT
schemes on lymph node involvement, all randomized trials
with preoperative RT for operable rectal cancer were
analyzed. Table 4 summarizes these trials with dose, frac-
tionation, and overall treatment time and the differences in
tumor stage, size, number of lymph nodes examined, and
histologic differentiation if published. The percentage of
stage III tumors is expressed in comparison with stage I and
II tumors unless otherwise stated. In general, the trials with
a long OTT demonstrate more downstaging than trials with
a short OTT. The SRC trial22 is divided in two subgroups:
patients with an OTT less than 10 days and patients with an
OTT greater than 10 days. Tumor size was smaller in all
irradiated groups than in the surgery-only groups.
To visualize the differences in the percentage of patients
with tumor-node-metastasis stage III, the 95% confidence
bars of the difference are plotted in Fig 3. The trials are
grouped by the duration of the OTT.
DISCUSSION
These results demonstrate that after short-term preopera-
tive RT, a decrease in the tumor size and the number of
recovered lymph nodes is observed, but there is no change
in the tumor classification and node classification. There-
fore, downstaging has not occurred in our trial. We suggest
that the disappearance of negative lymph nodes is caused by
rapid apoptosis of lymphocytes in contrast to tumor cells.
Preoperative RT is administered for several indications.
Apart from reduction in the number of local recurrences,
downstaging is one of the main purposes of conventional
schemes, which now are combined frequently with che-
motherapy. Tumor reduction is useful to achieve resect-
ability in locally advanced tumors or to allow sphincter-
saving procedures in low tumors. It is unlikely that a
greater number of sphincter-saving procedures can be
performed after short-term RT, because downstaging is
Table 3. Pathological Characteristics of Irradiated and Nonirradiated
Patients
RT 1 TME
(n 5 602)
TME
(n 5 719)
PNo. % No. %
Tumor diameter, cm , .001*
Mean 4.0 4.5
SD 1.7 1.8
Tumor stage .22†
0 4 0.7 13 1.8
Tis 2 0.3 4 0.6
1 33 6 33 5
2 203 34 219 30
3 346 57 419 58
4 14 2 31 4
Node stage .21†
Negative 369 61 416 58
Positive 233 39 303 42
Lymph nodes
Total examined
Mean 7.7 9.7 , .001*
SD 6.0 6.9
Positive in all patients
Mean 1.6 1.9 .11*
SD 3.6 4.1
Positive in node-positive
patients
Mean 4.2 4.5 .15*
SD 4.8 5.2
Histological differentiation , .001*
No tumor 4 13
Well 29 5 42 6
Moderate 360 60 495 71
Poor/undifferentiated 208 35 165 23
Missing 1 4
Tumor type , .001†
No tumor 4 13
Adenocarcinoma 518 87 651 93
Mucinous carcinoma 79 13 51 7
Missing 1 4
*Mann-Whitney U test.
†x2 test.
Fig 2. Distribution of Jass classification by randomization arm.
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not the mechanism by which the reduction in local
recurrence is achieved.
According to the literature, several factors seem to play a
role in the occurrence of downstaging after preoperative RT.
One factor is the fraction size and total dose applied. This is
directly correlated with the time interval between the first
fraction of RT and the date of surgery (the so-called OTT).
In studies in which doses of 40 Gy or more are given in a
conventional fractionation scheme, this automatically leads
to an OTT of more than 4 weeks, which provides time for
the tumor to shrink. In short-term RT, however, the overall
treatment time is usually 2 weeks at most. The relevance of
the interval between RT and surgery in rectal cancer has
been investigated recently by Francois et al.30 After a dose
of 30 to 39 Gy, they found no difference in stage III tumors
following an interval of 2 or 6 weeks between RT and
surgery. This might be explained by the median interval
between RT and surgery, which was already 13 days in the
short interval (range, 1 to 63 days).
There have been several reports on downstaging in rectal
cancer after randomized trials with preoperative RT. A sum-
mary of those studies is listed in Table 4 and Fig 3. Most
studies with an interval that exceeds 4 weeks demonstrate
fewer patients with Dukes’ C stage in the irradiated group. In
the European Organization for Research and Treatment of
Cancer trial,2 surgery was performed immediately after RT. No
difference in Dukes’ C staging was observed. The reports on
downstaging in the short-term RT group (, 2 weeks) varied.
No difference was seen (nor expected) in the Medical Research
Council I trial7 in the group that received 1 3 5 Gy or in the
Toronto trial. This can be attributed to the low total dose.
Of the other trials with a short OTT, most did not detect
downstaging. The SRC trial demonstrates less nodal in-
volvement if all patients are analyzed together. If the groups
are corrected for overall treatment time, the downstaging
disappears completely. The Stockholm II trial also demon-
strates downstaging, but of the 557 patients analyzed, 316
were also included in the report by Graf et al.10,22
In our study, the OTT was not more than 10 days. This
interval is too short for the tumor cells to disappear, and it
explains our finding that there was no downstaging. We
found smaller tumors in the RT arm, which is in accordance
with the trials mentioned previously. When tumor size was
reported, tumors were smaller in the RT group. To explain
the differences in tumor diameter, we investigated whether
the amount of lymphoid infiltration was a contributor. This
hypothesis was developed because the number of lymph
nodes found in the specimens decreased significantly in the
irradiated group, and we found less lymphoid infiltration in
irradiated tumors. There was no correlation between tumor
size and extension of infiltration.
The number of lymph nodes examined was significantly
lower in the irradiated group, but no decrease in the number of
positive lymph nodes was observed. This is explained by the
fact that lymphocytes can undergo cell death within hours after
RT without cell division, whereas tumor cells need more time
to undergo cell death.31 In patients with long intervals between
Table 4. Randomized Trials on Downstaging After Preoperative Radiotherapy for Rectal Cancer
Trial No. of Patients
Fraction 3
Dose, Gy
OTT
(weeks)
TNM III Tumor Size* Lymph Nodes† Histology‡
RT 1 S
(%)
S
(%)
RT 1 S
(%) S (%) RT 1 S S
RT 1 S
(%)
S
(%)
Bergen4 269 18 3 1.75 7 18 28 3.0 cm 4.0 cm 2 4 9 8
EORTC II2 341 15 3 2.3 4 34 34
VASOG II33 320 18 3 1.75 6 36 42
MRC II7 248 20 3 2 . 8 30 59 68 36 22 52 16 15
Toronto34 125 1 3 5 1 day 44 29
MRC I6 824 1 3 5 1 46 45 42 36 4.7 4.9 20 16
VASOG I35 613 10 3 2 . 2 24 38
MRC I6 824 10 3 2 3 36 45 54 36 3.2 4.9 15 16
RCG/ICRG3 468 3 3 5 1 43 44
NWRCG36 284 4 3 5 1-2 47§ 39§ 50 42 19 4
Stockholm I9 849 5 3 5 1-2 32 31 25 15
Stockholm II37 557 5 3 5 1-2 28 38
SRC22 1316 5 3 5 1-2 33 42 4.2 cm 4.8 cm
Current trial 1530 5 3 5 1-2 34 38 4.0 cm 4.5 cm 7.7 9.7 35 23
Abbreviations: TNM, tumo-node-metastasis stage; S, surgery; EORTC, European Organization for Research and Treatment of Cancer; VASOG, Veterans’
Administration Surgical Oncology Group; MRC, Medical Research Council; RCG/ICRG, Rectal Cancer Group/Imperial Cancer Research Fund; NWRCG,
Northwest Region Rectal Cancer Group; SRC, Swedish Rectal Cancer.
*Size in cm (Bergen median, others mean) or percentage of patients with tumors , 5 cm.
†Number of lymph nodes or percentage of patients with . 7 lymph nodes (MRC II).
‡Percentage of poorly differentiated tumors.
§TNM stage III and IV.
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RT and surgery, lymphocytes reappear and tumor cells die, and
these events lead to downstaging.
The differences in histology have been observed previously.
The Northwest Region Rectal Cancer Group trial and the
Stockholm I trial both reported an increase in poorly differen-
tiated tumors in the irradiated groups. This was not observed in
the Bergen and Medical Research Council II trial, both of
which had OTTs of more than 4 weeks; the disappearance of
cells is a possible explanation. Because grading is scored on
the basis of the worst area, the presence of less lymphocytes
increases the chance of finding such an area.
Despite the differences found after irradiation, no differ-
ence was found in tumor-node-metastasis stage. However,
the irradiated group demonstrated a higher Jass classifica-
tion, which resulted from the disappearance of the lympho-
cytic infiltrate, one of the Jass classification parameters.
Therefore, the Jass classification is of limited value in
comparing patients who have been irradiated preoperatively
with nonirradiated patients.
In January 2000, the Dutch Colorectal Cancer Group
initiated a new multicenter trial with optional randomization
for preoperative RT until the results of the TME trial are
known. Patients with tumor-node-metastasis stage II or III
are randomized postoperatively for adjuvant chemotherapy
(fluorouracil and leucovorin).32 The absence of downstag-
ing guarantees a balanced distribution of tumor-node-me-
tastasis stages across the different randomization groups,
which prevents stage migration that would influence the
eventual outcome of this new trial.
In addition, we conclude that short-term, preoperative RT
does not contribute to downstaging if the overall treatment
time is less than 10 days. Results that indicate better
survival or fewer recurrences after this type of RT must be
attributed to the effect of the RT.
Fig 3. Difference in percent-
age of tumor-node-metastasis
stage III in irradiated versus non
irradiated patients by trial. Ab-
breviations: EORTC, European
Organization for Research and
Treatment of Cancer; VASOG,
Veterans’ Administration Surgi-
cal Oncology Group; MRC, Med-
ical Research Council; RCG/
ICRG, Rectal Cancer Group/
Imperial Cancer Research Fund;
NWRCG, Northwest Region Rec-
tal Cancer Group; SRC, Swedish
Rectal Cancer.
Table 5. Jass Classification: Scoring Criteria
Criterion Score
Invasion through the bowel wall
Limited to bowel wall 0
Transmural 1
Margin of the tumor
Pushing 0
Infiltrating 1
Peritumoral lymphocytic infiltrate
Conspicious 0
Scant/absent 1
Lymph node metastases
Negative 0
1-4 positive 1
. 4 positive 2
Jass Groups Total Score
I 0-1
II 2
III 3
IV 4-5
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APPENDIX
The pathology review committee is as follows: E. Bloemena, Vrije Universiteit, Amsterdam; G. J. Offerhaus, Academisch Medisch Centrum,
Amsterdam; M.F.L. van Velthuysen, Antoni van Leeuwenhoekhuis, Amsterdam; J. Los, St. Ignatius Ziekenhuis, Breda; P.J. Westenend, PA
laboratorium, Dordrecht; H.M. Peters, I.W.N. Tan-Go, Stichting PAMM, Eindhoven; A.J.K. Grond, Lab. Volksgezondheid Friesland, Leeuwarden;
J.W. Arends, Academisch Ziekenhuis, Maastricht; A. Maes, J.C. Verhaar, Stichting Pathan, Rotterdam; and A.A.M. van der Wurff, Laboratorium
Centraal Brabant, Tilburg.
Cooperative clinical investigators include the following:
Surgeons: A.B. Bijnen, P. de Ruiter, Medisch Centrum Alkmaar, Alkmaar; B. van Ooijen, Algemeen Christelijk Ziekenhuis Eemland Locatie de
Lichtenberg, Mersfoort; D. van Geldere, R.P.A. Boom, Ziekenhuis Amstelveen, Amstelveen; R.P. Bleichrodt, S. Meyer, Academisch Ziekenhuis
Vrije Universiteit, Amsterdam; R.M.J.M. Butzelaar, E.Ph. Steller, Sint Lucas Andreas Ziekenhuis, Locatie Lucas, Amsterdam; W.F. van Tets,
A.C.H. Boissevain, Sint Lucas Andreas Ziekenhuis, Locatie Andreas, Amsterdam; F.J. Sjardin, BovenIJ Ziekenhuis, Amsterdam; J.F.M. Slors,
Academisch Medisch Centrum, Amsterdam; W.H. Bouma, J.G.J. Roussel, Gelre Ziekenhuizen, Locatie Lukas Ziekenhuiscentrum Apeldoorn,
Apeldoorn; J.H.G. Klinkenbijl, E.J. Spillenaar Bilgen, Ziekenhuis Rijnstate, Arnhem; Ph.M. Kruyt, W.K. de Roos, Stichting Ziekenhuisvoorzien-
ingen Gelderse Vallei Locatie Ziekenhuis Gelderse Vallei Bennekom, Bennekom; E.J.R. Slingenberg, P.D. de Rooij, Sint Ziekenhuis Lievensberg,
Bergen op Zoom; M.A.J.M. Hunfeld, Rode Kruis Ziekenhuis, Beverwijk; A.L.A. Meersman, Maasziekenhuis Boxmeer, Boxmeer; J.K.S. Nuytinck,
Ignatius Ziekenhuis Breda, Breda; R.M.P.H. Crolla, Ziekenhuis de Baronie, Breda; J. van der Bijl, Atrium Brunssum, Atrium Heerlen, Brunssum,
Heerlen; G.W.M. Tetteroo, IJsselland Ziekenhuis, CAPELLE A/D IJSSEL; L.P.S. Stassen, P.W. de Graaf, Reinier de Graaf Groep Loc. Reinier de
Graaf Gasthuis, Delft; W.A.H. Gelderman, F.G.J. Willekens, Bosch Medicentrum Locatie Groot Ziekengasthuis, Den Bosch; I.P.T. van Bebber,
E.J. Carol, Stichting Carolus-Liduina-Lindelust Ziekenhuis Locatie Carolus Ziekenhuis, Den Bosch; G.W. Kastelein, H. Boutkan, Stichting Juliana
Kinderziekenhuis/Rode Kruis Ziekenhuis Locatie Rode Kruis Ziekenhuis, Den Haag; Ch. Ulrich, B.C. de Vries, Medisch Centrum Haaglanden
Locatie Westeinde, Den Haag; H.J. Smeets, J.M. Heslinga, Stichting Bronovo-Nebo, Ziekenhuis Bronovo, Den Haag; W. H. Steup, P.V.M.
Pahlplatz, Ziekenhuis Leyenburg, Den Haag; P. Heres, J.A. van Oijen, Stichting het van Weel-Bethesda Ziekenhuis, Dirksland; M. van Hillo,
Stichting Talma Sionsberg, Dokkum; R.J. Oostenbroek, K.G. Tan, Albert Schweitzer Ziekenhuis Locatie Dordwijk, Dordrecht; H.C.J. van der Mijle,
Christelijk Ziekenhuis Nij Smellinghe, Drachten; R. Looijen, Christelijk Ziekenhuis Nij Smellinghe, Drachten; H.J.T. Rutten, J.J. Jakimowicz,
Catharina Ziekenhuis, Eindhoven; O.J. Repelaer van Driel, P. H. M. Reemst, Diaconessenhuis Eindhoven, Eindhoven; E.J.Th. Luiten, R.F.T.A.
Assmann, Sint Annaziekenhuis, GELDROP; C.M. Dijkhuis, Oosterscheldeziekenhuis, Goes; R.T. Ottow, Het Groene Hart Ziekenhuis Locatie
Bleuland, Gouda; J.T.M. Plukker, Academisch Ziekenhuis Groningen, Groningen; E.J. Boerma, R. Silvis, Kennemer Gasthuis Locatie Deo,
Haarlem; J.H. Tomee, Stichting Streekziekenhuis Coevorden-Hardenberg Locatie Röpcke Zweers, Hardenberg; G.J.M. Akkersdijk, Spaarne
Ziekenhuis, Heemstede; C.G.B.M. Rupert, de Tjongerschans, Ziekenhuis Heerenveen, Heerenveen; G.J.C.M. Niessen, G. Verspui, Elkerliek
Ziekenhuis Locatie Helmond, Helmond; J.H. Kroesen, J.W. Juttmann, Ziekenhuis Hilversum, Hilversum; J.W.D. de Waard, M.W.C. de Jonge,
Westfries Gasthuis Locatie Sint Jan, Hoorn; D.B.W. de Roy van Zuidewijn, W. Dahmen, Medisch Centrum Leeuwarden Locatie Zuid, Leeuwarden;
R. Vree, J.A. Zonnevylle, Diaconessenhuis Leiden, Leiden; C.J.H. van de Velde, R.A.E.M. Tollenaar, Lumc, Leiden; P.A. Neijenhuis, S.A. da
Costa, S.K. Adhin, Rijnland Ziekenhuis Locatie Sint Elisabeth, Leiderdorp; F.J. Idenburg, Medisch Centrum Haaglanden Locatie Antoniushove,
Leidschendam; H. van der Veen, IJsselmeerziekenhuizen Loc. Zuiderzeeziekenhuis, Lelystad; C.E.A.M. Hoynck van Papendrecht, IJsselmeerz-
iekenhuizen Locatie Zuiderzeeziekenhuis, Lelystad; C.G.M.I. Baeten, M.F. von Meyenfeldt, G.L. Beets, Academisch Ziekenhuis Maastricht,
Maastricht; T. Wobbes, Academisch Ziekenhuis Nijmegen Sint Radboud, Nijmegen; E.D.M. Bruggink, L.J.A. Strobbe, Canisius-Wilhelmina
Ziekenhuis Nijmegen, Nijmegen; O.J. van West, R.A.J. Dörr, Pasteurziekenhuis, Oosterhout; C.D. van Duyn, Ziekenhuis Bernhoven Locatie Oss,
OSS; J.W.M. Bol, Th.A.A. van den Broek, Waterlandziekenhuis, Purmerend; J.M.H. Debets, R. J. A. Estourgie, Laurentius Ziekenhuis, Roermond;
H.W.P.M. Kemperman, Ziekenhuis Franciscus, Roosendaal; H.F. Veen, W.F. Weidema, C.J. van Steensel, Ikazia Ziekenhuis, Rotterdam; F.
Logeman, A.A.E.A. de Smet, Sint Clara Ziekenhuis, Rotterdam; T. Wiggers, A.W.K. S. Marinelli, Academisch Ziekenhuis Rotterdam, Daniel den
Hoed Kliniek, Rotterdam; J.H. Driebeek-van Dam, Havenziekenhuis, Rotterdam; W.R. Schouten, P.P.L.O. Coene, Academisch Ziekenhuis
Rotterdam, Dijkzigt, Rotterdam; M.A. Paul, Zuiderziekenhuis, Rotterdam; J.J. van Bruggen, Schieland Ziekenhuis, Schiedam; E.J. Mulder,
Antonius Ziekenhuis, Sneek; R. den Toom, A.J. van Beek, Ruwaard van Putten Ziekenhuis, Spijkenisse; S.J. Brenninkmeyer, G.P. Gerritsen,
TweeSteden ziekenhuis, Tilburg; H.J.M. Oostvogel, J.A. Roukema, Sint Elisabeth Ziekenhuis, Tilburg; E.B.M. Theunissen, Mesos, Medisch
Centrum Locatie Overvecht, Utrecht; L.W.M. Janssen, A. Hennipman, Universitair Medisch Centrum Utrecht, Utrecht; A.J.M. van Wieringen,
Mesos, Medisch Centrum Locatie Oudenrijn, Utrecht; A. Pronk, P. Leguit, Diakonessenhuis, Utrecht; F. A.A.M. Croiset van Uchelen, R.M.H.
Roumen, Sint Joseph Ziekenhuis, Veldhoven; C.L.H. van Berlo, J.F.M. Reinders, Sint Maartens Gasthuis, Venlo; C.D.G.W. Verheij, Sint Elisabeth
Ziekenhuis, Venray; J.H. ten Thije, Ziekenhuis Walcheren, Vlissingen; W. van Overhagen, I.H. Oei, Reinier de Graaf Groep Locatie
Diaconessenhuis Voorburg, Voorburg; E.M.G. Leerkotte, J. W.A. van Luijt, TweeSteden ziekenhuis, Waalwijk; H.C.M. Verkooyen, J.A.L. Jansen,
Sint Jans-Gasthuis, Weert; J. Merkx, J.P. Vente, Hofpoort Ziekenhuis, Woerden; H. de Morree, Stichting Oosterscheldeziekenhuizen, Zierikzee;
P.J.J. van Rijn, ’t Lange Land Ziekenhuis, Zoetermeer; and W.F. Blom, Albert Schweitzer Ziekenhuis Locatie Zwijndrecht, Zwijndrecht.
Pathologists: J.P.A. Baak, Medisch Centrum Alkmaar, Alkmaar; H. Barrowclough, Algemeen Christelijk Ziekenhuis Eemland Locatie de
Lichtenberg, AMersfoort; G.J.A. Offerhaus, Academisch Medisch Centrum, Amsterdam; G. Brutel de la Riviere, Sint Lucas Andreas Ziekenhuis
Locatie Sint Lucas, Amsterdam; M.L.F. van Velthuysen, Antoni van Leeuwenhoekziekenhuis, Amsterdam; B.A. van de Wiel, Sint Lucas Andreas
Ziekenhuis Locatie Andreas, Amsterdam; H.H. Oushoorn, BovenIJ Ziekenhuis, Amsterdam; Th.A.J.M. Manschot, Gelre Ziekenhuizen Locatie
Lukas Ziekenhuiscentrum Apeldoorn, Apeldoorn; J.M. Wiersma-van Tilburg, Ziekenhuis Rijnstate, Arnhem; V. Potters, Stichting Ziekenhuis
Lievensberg, Bergen op Zoom; H.V. Stel, Ziekenhuis Gooi-Noord, Blaricum; J. Los, Ignatius Ziekenhuis Breda, Breda; G.W. Verdonk, Atrium
Brunssum, Brunssum; C. van Krimpen, S.H. Sastrowijoto, E.M. van der Loo, Stichting Diagnostisch Centrum Stichting Samenwerkende Delftse
Ziekenhuizen, Delft; H.A. Meijer, Bosch Medicentrum Locatie Groot Ziekengasthuis, Den Bosch; P. Blok, Ziekenhuis Leyenburg, Den Haag; C.J.
Tinga, Stichting Bronovo-Nebo, Ziekenhuis Bronovo, Den Haag; E.C.M. Ooms, Medisch Centrum Haaglanden Locatie Westeinde, Den Haag;
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APPENDIX (Cont’d)
C. M. Bruijn-van Duinen, Ziekenhuis Leyenburg, Den Haag; J.W. Steffelaar, Stichting Juliana Kinderziekenhuis/Rode Kruis Ziekenhuis Locatie
Rode Kruis Ziekenhuis, Den Haag; P.J. Westenend, Pathologisch Laboratorium voor Dordrecht en omstreken, Dordrecht; I. W. N. Tan-Go, H.M.
Peters, Stichting Pathologische Anatomie en Medische Microbiologie, Eindhoven; E.J.M. Ahsmann, Stichting LaboratoriaGoudse Ziekenhuizen,
Gouda; J. F. Keuning, Stichting Pathologisch Anatomisch Laboratorium Kennemerland, Haarlem; K. van Groningen, Spaarne Ziekenhuis,
Heemstede; P.H.M.H. Theunissen, Atrium Heerlen, Heerlen; F.J. J. M. van Merrienboer, Elkerliek Ziekenhuis Locatie Helmond, Helmond; G.
Freling, Ziekenhuis Bethesda, Hoogeveen; A.J.K. Grond, Laboratorium voor de Volksgezondheid in Friesland, Leeuwarden; M.C.B. Gorsira,
Diaconessenhuis Leiden, Leiden; J.J. Calame, Rijnland Ziekenhuis Locatie Sint Elisabeth, Leiderdorp; E.A. Neefjes-Borst, IJsselmeerziekenhuizen
Locatie Zuiderzeeziekenhuis, Lelystad; J.W. Arends, academisch ziekenhuis Maastricht, Maastricht; A. P. Runsink, Streeklaboratorium “Zeeland,”
Middelburg; C.A. Seldenrijk, Stichting Sint Antonius Ziekenhuis, Nieuwegein; J.H.J.M. van Krieken, Academisch Ziekenhuis Nijmegen St.
Radboud, Nijmegen; M. Mravunac, Canisius-Wilhelmina Ziekenhuis Nijmegen, Nijmegen; W.S. Kwee, Laurentius Ziekenhuis, Roermond; H. van
Dekken, Academisch Ziekenhuis Rotterdam, Daniel den Hoed Kliniek, Rotterdam; J.C. Verhaar, Stichting Pathan, Rotterdam; N.A. L. van Kaam,
Stichting Pathan, Rotterdam; H. van Dekken, Academisch Ziekenhuis Rotterdam, Dijkzigt, Rotterdam; R.W.M. Giard, Sint Clara Ziekenhuis,
Rotterdam; H. Beerman, Zuiderziekenhuis, Rotterdam; A.A.M. van der Wurff, Sint Elisabeth Ziekenhuis, Tilburg; M.E.I. Schipper, Universitair
Medisch Centrum Utrecht Locatie Academisch Ziekenhuis Utrecht, Utrecht; H.M. Ruitenberg, Diakonessenhuis, Utrecht; R.F.M. Schapers,
Stichting Pathologisch Laboratorium, Venlo; A.P. Willig, Sint Jans-Gasthuis, Weert; and A.G. Balk, Stichting Ziekenhuis De Heel, Zaandam.
Radiotherapists: E.H.J.M. Rutten, Medisch Centrum Alkmaar, Alkmaar; D. Gonzalez Gonzalez, G. van Tienhoven, Academisch Medisch
Centrum, Amsterdam; B.J. Slotman, J.A. Langendijk, Academisch Ziekenhuis Vrije Universiteit, Amsterdam; G.M.M. Bartelink, B.M.P. Aleman,
Antoni van Leeuwenhoekziekenhuis, Amsterdam; A. H. Westenberg, Arnhems Radiotherapeutisch Instituur, Arnhem; J. Pomp, Reinier de Graaf
Gasthuis, Delft; C.C.E. Koning, R.G.J. Wiggenraad, Medisch Centrum Haaglanden Locatie Westeinde, Den Haag; F.M. Gescher, Ziekenhuis
Leyenburg, Den Haag; J.J.F.M. Immerzeel, A.C.A. Mak, Radiotherapeutisch Instituut Stedendriehoek en Omstreken, Deventer; J.G. Ribot, H.
Martijn, Catharina Ziekenhuis, Eindhoven; D.F.M. de Haas-Kock, Stichting Radiotherapeutisch Instituut Limburg, Heerlen; G. Botke, A. Slot,
Radiotherapeutisch Instituut Friesland, Leeuwarden; E.M. Noordijk, Leids Universitair Medisch Centrum, Leiden; Ph. Lambin, Academisch
Ziekenhuis Maastricht, Maastricht; J.W.H. Leer, J. Hoogenhout, Academisch Ziekenhuis Nijmegen Sint Radboud, Nijmegen; Academisch
Ziekenhuis Nijmegen Sint Radboud, Nijmegen; P.C. Levendag, P.E.J. Hanssens, Academisch Ziekenhuis Rotterdam, Daniel den Hoed Kliniek,
Rotterdam; G.S.J. Bunnik, K.A.J. de Winter, dokter Bernard Verbeeten Instituut, Tilburg; J.J. Batterman, H.K. Wijrdeman, Universitair Medisch
Centrum Utrecht, Utrecht; and J.M. Tabak, M.F.H. Dielwart, Zeeuws Radiotherapeutisch Instituut, Vlissingen.
Note: A summary of the Jass classification system is listed in Table 5.
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